Second-line chemotherapy exposure in a German cancer society certified lung cancer center: Single-center experience of 4 years and relevance for maintenance therapy.

Abstract

e19097 Background: One of the strongest rationale for maintenance therapy in NSCLC is the fact that exposure to 2nd line therapy is only 40-60% in clinical trials in specialized treatment centers. Even with follow-up intervals of 6 weeks, the 2nd line treatment rate does not seem to increase. We analyzed the exposure of patients with stage IV NSCLC in one German Cancer Society certified Lung Cancer Center since certification, as long term follow-up data are available. Methods: All primary lung cancer cases stage IV in the lung cancer center were analyzed based on the documentation files between 2009 and 2013. Patients were followed between 1st and 2nd line therapy every 6-8 weeks according to S3 guidelines. Results: 267 patients were diagnosed with NSCLC IV (UICC7), or had systemic relapse of localized disease and were treated with 1st line therapy for metastatic disease. Of these, 168 (63%) received 1st line combination therapy with Carboplatin, 57 (21%) with Cisplatin, 29 (11%) with TKI 1st line therapy...